| Literature DB >> 33415265 |
Sara Amaniyan1, Akram Ghobadi2, Mojtaba Vaismoradi3.
Abstract
Despite the documented clinical efficacy, the injection of subcutaneous heparin can be associated with adverse drug reactions including bruising at the injection site. This study sought to systematically assess current evidence regarding the effect of cold application as a fundamental nursing intervention on the occurrence and size of bruising at the injection site in patients receiving subcutaneous heparin. A systematic review and meta-analysis of randomized controlled trials and quasi-experimental studies was performed. Web of Knowledge, PubMed (including MEDLINE), Scopus, Embase, Cochrane library, gray literature, and cross-referencing from reference lists were searched from 2000 to 2019. Quality of selected studies was assessed using the Cochrane risk of bias appraisal tool for randomized controlled trials and the JBI MASTARI appraisal tool for quasi-experimental studies. The search yielded 3,220 articles, but consideration of inclusion criteria led to final selection of 9 articles. The meta-analysis showed that cold application significantly reduced the relative occurrence of bruising at the subcutaneous heparin injection site by 40% (relative risk, 0.60; 95% confidence interval [0.39, 0.91]) and reduced the bruising size (standardized mean difference, -2.78; 95% confidence interval [-4.34, -1.22]). Cold application as a fundamental nursing intervention can be an effective intervention to prevent adverse drug reactions at the injection site in terms of the occurrence and size of bruising in patients receiving subcutaneous heparin.Entities:
Keywords: adverse drug reactions; cold application; low-molecular-weight heparin; medicines management; nursing intervention; patient safety; subcutaneous heparin
Year: 2020 PMID: 33415265 PMCID: PMC7774373 DOI: 10.1177/2377960820901370
Source DB: PubMed Journal: SAGE Open Nurs ISSN: 2377-9608
Search Strategy of This Review.
| 1. | “Heparin” OR “subcutaneous heparin” OR “Low Molecular Weight” OR “Enoxaparin” OR “Dalteparin” OR “Factor Xa Inhibitors” OR “Anticoagulants” |
| 2. | “Cryotherapy” OR “Cold compression” OR “Cold therapy” OR “Cold application” OR “Ice” |
| 3. | “Ecchymosis” OR “Bruising” OR “Hematoma” |
| 4. | 1 AND 2 AND 3 |
| 5. | “Clinical trial” OR “Randomized control trial” OR “Quasi-randomized controlled trial” OR “Quasi-experimental study” |
Figure 1.The selection process according to the PRISMA flow diagram.
Summary of the Characteristics of the Selected Studies.
| Studies | Country | Study design | Samplea ( | Age-group | Anticoagulant | Cold application | Outcome |
|---|---|---|---|---|---|---|---|
|
| Egypt | Quasi-Experimental | 70 | Adults | Subcutaneous heparin | For 5 minutes after the injection | Bruising occurrence and bruising size |
|
| India | Quasi-Experimental | 60 | Adults | Subcutaneous heparin | For 20 minutes after the injection | Bruising size |
|
| Iran | RCT | 120 | Adults | Subcutaneous heparin | For 20 minutes after the injection | Bruising occurrence and bruising size |
|
| India | RCT | 25 | Adults | Subcutaneous heparin | For 3 minutes after the injection | Bruising size |
|
| Turkey | RCT | 40 | Adults | Subcutaneous heparin | For 5 minutes after the injection | Bruising occurrence and bruising size |
|
| India | Quasi-Experimental | 60 | Adults | Subcutaneous heparin | For 3 to 5 minutes before the injection | Bruising size |
|
| Turkey | Quasi-Experimental | 54 | Adults | Subcutaneous heparin | For 2 minutes before the injection | Bruising occurrence and bruising size |
|
| India | RCT | NA (200 injection sites) | Adults | Subcutaneous heparin | For 5 minutes after the injection | Bruising occurrence and bruising size |
|
| Turkey | RCT | 32 | Adults | Subcutaneous heparin | For 5 minutes after the injection | Bruising occurrence and bruising size |
RCT = randomized controlled trial; NA = not applicable.aReported sample size may not be equal to the total number of included patients in the corresponding study. Other groups that received a different intervention were not considered.
Figure 2.Meta-analysis of the bruising incidence in the RCTs (based on the fixed effect model) and the quasi-experimental studies (based on the random-effect model). RCT = randomized controlled trial; RR = relative risk; CI = confidence interval.
Figure 3.Meta-analysis for the bruising size in the RCTs (based on the random effect model) and the quasi-experimental studies (based on the fixed-effect model). RCT = randomized controlled trial; SD = standard deviation; SMD = standardized mean difference; CI = confidence interval.
Risk of Bias in the Randomized Control Trials.
| Random sequence generation | Allocation concealment | Blinding | Incomplete outcome data | Selective outcome reporting | Other sources of bias | |
|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
= low risk of bias; = high risk of bias; = unclear risk of bias.
Risk of Bias in the Quasi-Experimental Studies.
| Study | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ruamp et al. (2018) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
= low risk of bias; = high risk of bias; = unclear risk of bias.
Q1: Was the assignment to treatment groups truly random?; Q2: Were participants blinded to treatment allocation?; Q3: Was allocation to treatment groups concealed from the allocator?; Q4: Were the outcomes of people who withdrew described and included in the analysis?; Q5: Were those assessing the outcomes blind to the treatment allocation?; Q6: Were control and treatment groups comparable?; Q7: Were groups treated identically other than for the named intervention?; Q8: Were outcomes measured in the same way for all groups?; Q9: Were outcomes measured in a reliable way?; Q10: Was appropriate statistical analysis used?